West Pharmaceutical
468 hedge funds and large institutions have $10.3B invested in West Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 169 increasing their positions, 161 reducing their positions, and 41 closing their positions.
100% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $7.08M
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
68% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 41
5% more funds holding
Funds holding: 445 → 468 (+23)
5% more repeat investments, than reductions
Existing positions increased: 169 | Existing positions reduced: 161
1% more capital invested
Capital invested by funds: $10.2B → $10.3B (+$56.7M)
0.48% less ownership
Funds ownership: 91.8% → 91.31% (-0.48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCP
Durable Capital Partners
Bethesda,
Maryland
|
+$145M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$66.5M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$60.1M |
| 4 |
BlackRock
New York
|
+$46.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$233M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$68.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$57.6M |
| 4 |
JP Morgan Chase
New York
|
-$56.1M |
| 5 |
Millennium Management
New York
|
-$43M |
WST Hedge Fund Activity: Q1 2020 in Review
468 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2020, worth a combined $10.3B — up 0.56% from $10.2B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new WST positions and 41 closed out — a net gain of 28 holders — while 169 added to existing stakes and 161 trimmed.
The largest buyer was Durable Capital Partners, opening a new position worth an estimated $145M. The largest seller was T. Rowe Price Associates, cutting an estimated $233M.
- 468 institutional investors held West Pharmaceutical (WST) as of Q1 2020, up from 445 in Q4 2019.
- Funds reported $10.3B of West Pharmaceutical stock for Q1 2020, up 0.56% quarter-over-quarter.
- 69 funds opened new West Pharmaceutical positions in Q1 2020 and 41 closed out, a net change of +28 holders.
- The largest West Pharmaceutical buyer in Q1 2020 was Durable Capital Partners, an estimated $145M added.
- The largest West Pharmaceutical seller in Q1 2020 was T. Rowe Price Associates, an estimated $233M sold.
Based on aggregated 13F filings for Q1 2020.